Microbiological efficacy of ABT-773 (cethromycin) for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae

Journal of Antimicrobial Chemotherapy

Volumn 51, Issue 4, 2003, Pages 1025-1028

  Hammerschlag, Margaret R ^a   Reznik, Tamara ^a   Roblin, Patricia M ^a   Ramirez, Julio ^b   Summersgill, James ^b   Bukofzer, Stanley ^c  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

^b University of Louisville School of Medicine   (United States)

^c ABBOTT LABORATORIES   (United States)

Author keywords

C. pneumoniae; Chlamydia; Ketolide

Indexed keywords

AMPHOTERICIN B; AZITHROMYCIN; CETHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; GENTAMICIN; KETOLIDE; MACROLIDE; TELITHROMYCIN; VANCOMYCIN;

ADULT; AGED; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL PNEUMONIA; BACTERIUM CULTURE; BACTERIUM ISOLATE; CHLAMYDOPHILA PNEUMONIAE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; NASOPHARYNX; PHASE 3 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; DOUBLE-BLIND METHOD; ERYTHROMYCIN; FEMALE; HUMANS; KETOLIDES; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NASOPHARYNX; PNEUMONIA, BACTERIAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0037398792     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkg154     Document Type: Article

References (12)

1. File, T. M., Bartlett, J. G., Cassell, G. H., Gaydos, C. A., Grayston, J. T., Hammerschlag, M. R. et al. (1997). The importance of Chlamydia pneumoniae as a pathogen: the 1996 Consensus Conference on Chlamydia pneumoniae infections. Infectious Diseases in Clinical Practice 6, Suppl. 2, S28-31.
2. Block, S. J., Hedrick, J., Hammerschlag, M. R., Cassell, G. H. & Craft, C. (1995). Mycoplasma pneumoniae and Chlamydia pneumoniae in pediatric community-acquired pneumonia: comparative efficacy and safety of clarithromycin vs erythromycin ethylsuccinate. Pediatric Infectious Disease Journal 14, 471-7.
3. Roblin, P. M. & Hammerschlag, M. R. (1998). Microbiologic efficacy of azithromycin and susceptibility to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community acquired pneumonia. Antimicrobial Agents and Chemotherapy 42, 194-6.
4. Strigl, S., Roblin, P. M., Reznik, T. & Hammerschlag, M. R. (2000). In vitro activity of ABT 773, a new ketolide antibiotic, against Chlamydia pneumoniae. Antimicrobial Agents and Chemotherapy 44, 1112-3.
5. Fine, M. J., Auble, T. E., Yealy, D. M., Hanusa, B. H., Weissfeld, L. A., Singer, D. E. et al. (1997). A prediction rule to identify low-risk patients with community-acquired pneumonia. New England Journal of Medicine 336, 243-50.
6. Ramirez, J. A., Ahkee, S., Tolentino, A., Miller, R. D. & Summersgill, J. T. (1996). Diagnosis of Legionella pneumophila, Mycoplasma pneumoniae or Chlamydia pneumoniae lower respiratory infection using the polymerase chain reaction on a single throat swab specimen. Diagnostic Microbiology and Infectious Disease 24, 7-14.
7. Miyashita, N., Fukano, H., Niki, Y. & Matsushima, T. (2001). In vitro activity of telithromycin, a new ketolide, against Chlamydia pneumoniae. Journal of Antimicrobial Chemotherapy 48, 403-5.
8. Dowell, S. F., Peeling, R. W., Boman, J., Carlone, G. M., Fields, B. S., Guarner, J. et al. (2001). Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clinical Infectious Diseases 33, 492-503.
9. Hammerschlag, M. R. & Roblin, P. M. (2000). Microbiologic efficacy of moxifloxacin for the treatment of community-acquired pneumonia due to Chlamydia pneumoniae. International Journal of Antimicrobial Agents 15, 149-52.
10. Hammerschlag, M. R., Reznik, T. & Roblin, P. (2001). Microbiologic efficacy of levofloxacin for the treatment of serious community-acquired pneumonia due to Chlamydia pneumoniae. Journal of Antimicrobial Chemotherapy 47, Suppl. S1, Abstract P112, p. 45.
11. Barry, A. L., Fuchs, P. C. & Brown, S. D. (2001). In vitro activity of the ketolide ABT-773. Antimicrobial Agents and Chemotherapy 45, 2922-4.
12. Jung, R., Danziger, L. H. & Pendland, S. L. (2002). Intracellular activity of ABT-773 and other antimicrobial agents against Legionella pneumophila. Journal of Antimicrobial Chemotherapy 49, 857-61.